Philogen S.p.A.

49 clinical trials · Sponsor

Record	Firm	Date
L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma (NCT07228442)	Philogen S.p.A.	2026-09-01
L19IL2/TNF in Patients With Basal Cell Carcinoma (NCT07227870)	Philogen S.p.A.	2026-09-01
L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC) (NCT07227350)	Philogen S.p.A.	2026-06-01
A Phase I Study to Evaluate the Safety and Dosimetry of Imaging With 68Ga-OncoACP3 in Prostate Cancer (NCT07600554)	Philogen S.p.A.	2026-05-27
A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors (NCT07566897)	Philogen S.p.A.	2026-05-01
A Study of F8IL10 Intra-articular Treatment in Rheumatoid Arthritis (NCT07245992)	Philogen S.p.A.	2026-03-04
A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or Oligodendroglioma (NCT07120984)	Philogen S.p.A.	2026-01-30
A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors (NCT06640413)	Philogen S.p.A.	2025-10-31
A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients With CAIX-positive Cancer (NCT06840548)	Philogen S.p.A.	2025-04-16
A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoACP3 in Patients With Prostate Cancer (NCT06840535)	Philogen S.p.A.	2025-04-08
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients (NCT06284590)	Philogen S.p.A.	2024-07-12
A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence (NCT06336291)	Philogen S.p.A.	2024-05-22
A Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Solid Tumors (NCT05784597)	Philogen S.p.A.	2023-04-27
Safety and Preliminary Signs of Efficacy of F8IL10 for Intra-articular Treatment (NCT05622175)	Philogen S.p.A.	2023-03-31
L19IL2/L19TNF in Skin Cancer Patients (NCT05329792)	Philogen S.p.A.	2023-03-09
Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression (NCT05304663)	Philogen S.p.A.	2022-06-01
A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression (NCT04573192)	Philogen S.p.A.	2021-02-19
Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma (NCT04443010)	Philogen S.p.A.	2021-01-20
Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients (NCT04362722)	Philogen S.p.A.	2020-09-02
Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma (NCT04733183)	Philogen S.p.A.	2020-08-28
Safety and Early Signs of Efficacy of IL12-L19L19. (NCT04471987)	Philogen S.p.A.	2020-07-01
Dose Finding Study of L19TNF and Doxorubicin in Patients With STS (NCT04032964)	Philogen S.p.A.	2019-09-05
Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse (NCT03779230)	Philogen S.p.A.	2019-05-31
Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA) (NCT03420014)	Philogen S.p.A.	2018-12-27
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients (NCT03567889)	Philogen S.p.A.	2018-09-20
A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma (NCT04650984)	Philogen S.p.A.	2017-11-29

Track Philogen S.p.A. automatically

Every clearance here is in the API, with alerts when new ones post.